Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma

Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma

Blockade of the immune checkpoints programmed death-1 (PD-1) and cytotoxic lymphocyte antigen 4 has improved outcomes for patients with hepatocellular carcinoma (HCC), yet most still fail to achieve objective clinical benefit. MET plays key roles in both HCC tumorigenesis and immunosuppressive condi...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael A Curran, Joanna Schmidt, Ahmed O Kaseb, Arthur Liu, Madeline Steiner, Ricardo DeAzevedo, Broderick X Turner, Sherwin Newton, Rachel Fleming, Angelica Tolentino
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e009690.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/10/e009690.full

Similar Items